Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial

✍ Scribed by Nicholas D. James; Armelle Caty; Heather Payne; Michael Borre; Bernard A. Zonnenberg; Philippe Beuzeboc; Stuart McIntosh; Thomas Morris; De Phung; Nancy A. Dawson

• Book ID: 110923155
• Publisher: John Wiley and Sons
• Year: 2010
• Tongue: English
• Weight: 428 KB
• Volume: 106
• Category: Article
• ISSN: 1464-4096
• DOI: 10.1111/j.1464-410x.2010.09638.x